Phenotype and imaging features associated with APP duplications.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
11 05 2023
Historique:
received: 19 08 2022
accepted: 18 01 2023
medline: 15 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: epublish

Résumé

APP duplication is a rare genetic cause of Alzheimer disease and cerebral amyloid angiopathy (CAA). We aimed to evaluate the phenotypes of APP duplications carriers. Clinical, radiological, and neuropathological features of 43 APP duplication carriers from 24 French families were retrospectively analyzed, and MRI features and cerebrospinal fluid (CSF) biomarkers were compared to 40 APP-negative CAA controls. Major neurocognitive disorders were found in 90.2% symptomatic APP duplication carriers, with prominent behavioral impairment in 9.7%. Symptomatic intracerebral hemorrhages were reported in 29.2% and seizures in 51.2%. CSF Aβ42 levels were abnormal in 18/19 patients and 14/19 patients fulfilled MRI radiological criteria for CAA, while only 5 displayed no hemorrhagic features. We found no correlation between CAA radiological signs and duplication size. Compared to CAA controls, APP duplication carriers showed less disseminated cortical superficial siderosis (0% vs 37.5%, p = 0.004 adjusted for the delay between symptoms onset and MRI). Deep microbleeds were found in two APP duplication carriers. In addition to neurofibrillary tangles and senile plaques, CAA was diffuse and severe with thickening of leptomeningeal vessels in all 9 autopsies. Lewy bodies were found in substantia nigra, locus coeruleus, and cortical structures of 2/9 patients, and one presented vascular amyloid deposits in basal ganglia. Phenotypes associated with APP duplications were heterogeneous with different clinical presentations including dementia, hemorrhage, and seizure and different radiological presentations, even within families. No apparent correlation with duplication size was found. Amyloid burden was severe and widely extended to cerebral vessels as suggested by hemorrhagic features on MRI and neuropathological data, making APP duplication an interesting model of CAA.

Sections du résumé

BACKGROUND
APP duplication is a rare genetic cause of Alzheimer disease and cerebral amyloid angiopathy (CAA). We aimed to evaluate the phenotypes of APP duplications carriers.
METHODS
Clinical, radiological, and neuropathological features of 43 APP duplication carriers from 24 French families were retrospectively analyzed, and MRI features and cerebrospinal fluid (CSF) biomarkers were compared to 40 APP-negative CAA controls.
RESULTS
Major neurocognitive disorders were found in 90.2% symptomatic APP duplication carriers, with prominent behavioral impairment in 9.7%. Symptomatic intracerebral hemorrhages were reported in 29.2% and seizures in 51.2%. CSF Aβ42 levels were abnormal in 18/19 patients and 14/19 patients fulfilled MRI radiological criteria for CAA, while only 5 displayed no hemorrhagic features. We found no correlation between CAA radiological signs and duplication size. Compared to CAA controls, APP duplication carriers showed less disseminated cortical superficial siderosis (0% vs 37.5%, p = 0.004 adjusted for the delay between symptoms onset and MRI). Deep microbleeds were found in two APP duplication carriers. In addition to neurofibrillary tangles and senile plaques, CAA was diffuse and severe with thickening of leptomeningeal vessels in all 9 autopsies. Lewy bodies were found in substantia nigra, locus coeruleus, and cortical structures of 2/9 patients, and one presented vascular amyloid deposits in basal ganglia.
DISCUSSION
Phenotypes associated with APP duplications were heterogeneous with different clinical presentations including dementia, hemorrhage, and seizure and different radiological presentations, even within families. No apparent correlation with duplication size was found. Amyloid burden was severe and widely extended to cerebral vessels as suggested by hemorrhagic features on MRI and neuropathological data, making APP duplication an interesting model of CAA.

Identifiants

pubmed: 37170141
doi: 10.1186/s13195-023-01172-2
pii: 10.1186/s13195-023-01172-2
pmc: PMC10173644
doi:

Substances chimiques

Amyloid 0
APP protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

93

Informations de copyright

© 2023. The Author(s).

Références

Stroke. 2014 Oct;45(10):2930-5
pubmed: 25116879
JAMA Neurol. 2021 Sep 1;78(9):1080-1090
pubmed: 34279544
J Alzheimers Dis. 2019;71(1):227-243
pubmed: 31381512
Neurology. 2019 Jul 23;93(4):e358-e371
pubmed: 31243071
Neurology. 2017 Nov 21;89(21):2128-2135
pubmed: 29070669
PLoS Med. 2017 Mar 28;14(3):e1002270
pubmed: 28350801
Lancet. 2020 Jun 27;395(10242):1988-1997
pubmed: 32593336
J Alzheimers Dis. 2022;87(2):791-802
pubmed: 35367960
Neurology. 2016 Aug 30;87(9):912-9
pubmed: 27466472
Clin Chem. 2019 Sep;65(9):1153-1160
pubmed: 31292136
Nat Genet. 2006 Jan;38(1):24-6
pubmed: 16369530
J Alzheimers Dis. 2015;44(1):103-14
pubmed: 25182745
Radiology. 2018 Apr;287(1):11-28
pubmed: 29558307
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879
Neurol Genet. 2021 Sep 08;7(5):e609
pubmed: 34532568
J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72
pubmed: 1431963
J Alzheimers Dis. 2013;37(4):789-93
pubmed: 23948920
Stroke. 2018 Feb;49(2):491-497
pubmed: 29335334
Neurology. 2008 Dec 2;71(23):1925-6
pubmed: 19047566
Stroke. 2018 Aug;49(8):1913-1919
pubmed: 30012821
Mol Psychiatry. 2015 Sep;20(9):1046-56
pubmed: 26194182
J Alzheimers Dis. 2017;56(1):37-46
pubmed: 27858710
F1000Res. 2016 May 12;5:
pubmed: 27239286
J Alzheimers Dis. 2012;28(3):561-6
pubmed: 22045488
Neurology. 2020 Dec 15;95(24):e3331-e3343
pubmed: 32913026
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
Brain. 2006 Nov;129(Pt 11):2966-76
pubmed: 16959815
J Alzheimers Dis. 2012;30(4):847-56
pubmed: 22475797
Nat Neurosci. 2010 Jul;13(7):812-8
pubmed: 20581818
Brain. 2006 Nov;129(Pt 11):2977-83
pubmed: 16921174
PLoS Med. 2021 Sep 23;18(9):e1003801
pubmed: 34555025
J Neural Transm (Vienna). 2009 Feb;116(2):203-12
pubmed: 19142572
Alzheimers Dement. 2016 Jun;12(6):733-48
pubmed: 27016693
Nat Rev Neurol. 2020 Jan;16(1):30-42
pubmed: 31827267
Stroke. 2018 Jun;49(6):1518-1520
pubmed: 29695466
Mol Psychiatry. 2021 Oct;26(10):5766-5788
pubmed: 32647257
Acta Neuropathol. 2018 Oct;136(4):569-587
pubmed: 29770843
Neurology. 2014 Nov 11;83(20):1838-43
pubmed: 25320098
J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):1050-2
pubmed: 19684239
Alzheimers Res Ther. 2014 Jun 26;6(3):38
pubmed: 25478015
J Neurol Neurosurg Psychiatry. 2021 Feb 9;:
pubmed: 33563804
Rev Neurosci. 2014;25(5):641-51
pubmed: 24870607
Cerebrovasc Dis. 2002;13 Suppl 2:31-6
pubmed: 11901240
Acta Neuropathol. 2019 Feb;137(2):183-207
pubmed: 30478624
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):901-8
pubmed: 23457231
Brain. 2015 Aug;138(Pt 8):2126-39
pubmed: 26115675

Auteurs

Lou Grangeon (L)

Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France. lou.grangeon@chu-rouen.fr.
Department of Neurology, Rouen University Hospital, Rouen Cedex, 76031, France. lou.grangeon@chu-rouen.fr.

Camille Charbonnier (C)

Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Aline Zarea (A)

Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Stephane Rousseau (S)

Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Anne Rovelet-Lecrux (A)

Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

David Bendetowicz (D)

Neurology Department, Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS and APHP, Hôpital de la Pitié-Salpétrière APHP, Paris, France.

Marion Lemaitre (M)

Geriatric department, Seclin-Carvin Hospital, Seclin, France.

Cécile Malrain (C)

Department of Neurology, Rennes Hospital, Rennes, France.

Muriel Quillard-Muraine (M)

Laboratoire de biochimie, Rouen University Hospital and University of Rouen, Rouen, France.

Kevin Cassinari (K)

Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

David Maltete (D)

Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Jeremie Pariente (J)

Neurology Department, Toulouse University Hospital and Toulouse NeuroImaging Center (ToNIC) INSERM-Univeristy of Toulouse Paul Sabatier, Toulouse, France.

Olivier Moreaud (O)

Department of Neurology, Grenoble Hospital, Grenoble, France.

Eloi Magnin (E)

Department of Neurology, Besancon Hospital, Besancon, France.

Benjamin Cretin (B)

Department of Neurology, Hautepierre Hospital, Strasbourg, France.

Marie-Anne Mackowiak (MA)

Univ. Lille, CHU Lille, CNRMAJ, 59000, Lille, France.

Adeline Rollin Sillaire (AR)

Univ. Lille, CHU Lille, CNRMAJ, 59000, Lille, France.

Martine Vercelletto (M)

Department of Neurology, Nantes University Hospital, Nantes, France.

Elsa Dionet (E)

Department of Neurology, Clermont-Ferrand Hospital, Clermont-Ferrand, France.

Olivier Felician (O)

APHM, Service de Neurologie et Neuropsychologie, CHU Timone, Marseille, France.
Aix Marseille Univ, INSERM, INS, Inst Neurosci Syst, Marseille, France.

Pauline Rod-Olivieri (P)

Neurology Department, Hôpital Saint Anne APHP, Paris, France.

Catherine Thomas-Antérion (C)

Department of Neurology, Lyon University Hospital, Lyon, France.

Gaelle Godeneche (G)

Department of Neurology, La Rochelle Hospital, La Rochelle, France.

Mathilde Sauvée (M)

Department of Neurology, Grenoble Hospital, Grenoble, France.

Leslie Cartz-Piver (L)

Centre Mémoire Ressources et Recherche (CMRR), Limoges University Hospital, Limoges, France.

Isabelle Le Ber (I)

Neurology Department, Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS and APHP, Hôpital de la Pitié-Salpétrière APHP, Paris, France.

Valérie Chauvire (V)

Department of Neurology, Angers University Hospital, Angers, France.

Therèse Jonveaux (T)

Department of Neurology, Nancy University Hospital, Nancy, France.

Anna-Chloé Balageas (AC)

CHRU Tours, Centre Mémoire Ressources et Recherche (CMRR), Tours, France.

Annie Laquerriere (A)

Department of Neuropathology, F 76000, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.

Charles Duyckaerts (C)

Sorbonne Unviersité, INSERM, CNRS U1127, ICM and Laboratoire de Neuropathologie R. Escourolle, Hospital Pitie-Salpêtrière, Paris, France.

Anne Vital (A)

Department of Pathology, University Hospital, Bordeaux, France.

Andre Maues de Paula (AM)

Department of Pathology, La Timone University Hospital, Marseille, France.

David Meyronet (D)

Department of Pathology, Hopital Civil University Hospital, Lyon, France.

Lucie Guyant-Marechal (L)

Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Didier Hannequin (D)

Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Elisabeth Tournier-Lasserve (E)

AP-HP, Groupe Hospitalier Saint-Louis Lariboisière-Fernand-Widal, Service de Génétique Moléculaire Neurovasculaire, INSERM UMR 1141, NeuroDiderot, Université de Paris, Paris, France.

Dominique Campion (D)

Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Gaël Nicolas (G)

Department of Genetics and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

David Wallon (D)

Department of Neurology and CNR-MAJ, Univ Rouen Normandie, U1245 and CHU Rouen, 76000, Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH